1Fossella F,Pereira JR,von Pawel J,et al.Randomized,multinational,phase Ⅲ study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer:the TAX 326 study group.J Clin Oncol,2003,21:3016-3024.
2Smith IE,O'Brien ME,Talbot DC,et al.Duration of chemotherapy in advanced non-small-cell lung cancer:a randomized trial of three versus six courses of mitomycin,vinblastine,and cisplatin.J Clin Oncol,2001,19:1336-1343.
3Georgoulias V,Papadakis E,Alexopoulos A,et al.Platinumbased and non-platinum-based chemotherapy in advanced non-small-cell lung cancer:a randomised multicentre trial.Lancet,2001,357:1478-1484.
4Lilenbaum RC,Herndon JE 2nd,List MA,et al.Single-agent versus combination chemotherapy in advanced non-small-cell lung cancer:the cancer and leukemia group B (study 9730).J Clin Oncol,2005,23:190-196.
5Lilenbaum RC,Langenberg P,Dickersin K.Single agent versus combination chemotherapy in patients with advanced nonsmall cell lung carcinoma:a meta-analysis of response,toxicity,and survival.Cancer,1998,82:116-126.
6Kelly K,Crowley J,Bunn PA Jr,et al.Randomized phase Ⅲ trial of paclitaxel plus carboplatin versus vinorelbine plus cisplatin in the treatment of patients with advanced non-small-cell lung cancer:a Southwest Oncology Group trial.J Clin Oncol,2001,19:3210-3218.
7Rosell R,Gatzemeier U,Betticher DC,et al.Phase Ⅲ randomised trial comparing paclitaxel/carboplatin with paclitaxel/cisplatin in patients with advanced non-small-cell lung cancer:a cooperative multinational trial.Ann Oncol,2002,13:1539-1549.
8Langer CJ,Manola J,Bernardo P,et al.Cisplatin-based therapy for elderly patients with advanced non-small-cell lung cancer:implications of Eastern Cooperative Oncology Group 5592,a randomized trial.J Natl Cancer Inst,2002,94:173-181.
9Hanna N,Shepherd FA,Fossella FV,et al.Randomized phase Ⅲ trial of pemetrexed versus docetaxel in patients with non-small-cell lung cancer previously treated with chemotherapy.J Clin Oncol,2004,22:1589-1597.
10Socinski MA,Schell MJ,Peterman A,et al.Phase Ⅲ trial comparing a defined duration of therapy versus continuous therapy followed by second-line therapy in advanced-stage Ⅲ B/Ⅳ non-small-cell lung cancer.J Clin Oncol,2002,20:1335-1343.
